Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future (original) (raw)
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
Mihály Makara
The lancet. Gastroenterology & hepatology, 2017
View PDFchevron_right
Market uptake of new antiviral drugs for the treatment of hepatitis C
Ruth Schwarzer
Journal of Hepatology, 2008
View PDFchevron_right
Cost-Effectiveness of Boceprevir Add-On Treatment of Hepatitis C Virus Genotype 1 Patients in Denmark
Lars Ehlers
Value in Health, 2013
View PDFchevron_right
Incremental cost-effectiveness pharmacoeconomic assessment of hepatitis C virus therapy: an approach for less wealthy members of the common market
Davor Mance
Croatian Medical Journal, 2016
View PDFchevron_right
Drug Pricing Evolution in Hepatitis C
François Girardin
PLOS ONE, 2016
View PDFchevron_right
A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients
Maria Phelan, Catherine Cook
BMC infectious diseases, 2014
View PDFchevron_right
Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
Colm Bergin
BMC Infectious Diseases, 2015
View PDFchevron_right
New Perspective in HCV Clinical and Economical Management of the Current and Future Therapies
A. Serafino
Recent Advances in Liver Diseases and Surgery, 2015
View PDFchevron_right
Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy
Carlo Drago
Applied Health Economics and Health Policy, 2018
View PDFchevron_right
Pharmacoeconomic analysis of treatment of patients infected with hepatitis C virus
Muhammad Tahir Aziz
PubMed, 2018
View PDFchevron_right
The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies
Soo Aleman
Scandinavian Journal of Gastroenterology, 2015
View PDFchevron_right
Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial
Ulrich Alshuth
Journal of Viral Hepatitis, 2015
View PDFchevron_right
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
Shannon Ferrante
BMC Infectious Diseases, 2013
View PDFchevron_right
Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe
Leondios Kostrikis
Journal of Hepatology, 2017
View PDFchevron_right
Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-Effectiveness Analysis
Ilias-Ioannis Kyriopoulos
Clinical Therapeutics, 2015
View PDFchevron_right
Elimination of hepatitis C virus infection in Europe: targeting the obstacles
Dante Romagnoli
Exploration of Medicine, 2022
View PDFchevron_right
Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C
Ruth Schwarzer
Journal of Viral Hepatitis, 2000
View PDFchevron_right
Hepatitis C: When high drug prices preclude patient benefit
Shilpa Elizabeth Paul
Cancer, 2018
View PDFchevron_right
Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C
Donald Anthony
PloS one, 2016
View PDFchevron_right
Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C
Miguel Casado
Journal of Hepatology, 2005
View PDFchevron_right
Lowering the High Cost of Hepatitis C Drugs
Audrey Chapman
Journal of Pharmaceutical Care & Health Systems, 2017
View PDFchevron_right
Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals
Angelo Lamberti
BMC Infectious Diseases, 2014
View PDFchevron_right
Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C
Prem Thurairajah
Antiviral Therapy, 2012
View PDFchevron_right
The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia
M. Van Driel
ClinicoEconomics and Outcomes Research: CEOR, 2017
View PDFchevron_right
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the United States
haikal fikri
Journal of medical economics, 2016
View PDFchevron_right
Predictable threats to public health through delaying universal access to innovative medicines for Hepatitis C: A pharmaceutical standpoint
Anja De Weggheleire
Tropical Medicine & International Health, 2016
View PDFchevron_right
Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study
Nancy French van Emmerik
Cogent Medicine
View PDFchevron_right